Genomic-Guided Radiation Therapy for Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) in people with triple negative (HER2 negative, hormone receptor negative) breast cancer undergoing breast conservation therapy.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.
Is Genomic-Guided Radiation Therapy safe for humans?
How is Genomically Guided Radiation Therapy different from other breast cancer treatments?
Genomically Guided Radiation Therapy is unique because it uses genetic information to tailor radiation treatment specifically to the patient's tumor, potentially improving effectiveness and reducing unnecessary exposure compared to standard radiation therapy, which does not typically use genomic data for personalization.678910
What data supports the effectiveness of the treatment Genomically Guided Radiation Therapy for Breast Cancer?
Research suggests that using genomic information to guide radiation therapy can potentially improve treatment by tailoring it to individual genetic profiles, which may enhance tumor control and reduce side effects. Advances in understanding genetic variations have already been integrated into clinical practice for other cancers, indicating a promising future for personalized radiation therapy in breast cancer.16111213
Who Is on the Research Team?
Kamran Ahmed, M.D.
Principal Investigator
Moffitt Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with triple negative breast cancer who've had a lumpectomy and axillary evaluation. They must not be pregnant or breastfeeding, have recovered from recent surgeries, and agree to use effective contraception. Participants need a life expectancy over 16 weeks and a performance status score of at least 70.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive genomically guided radiation therapy or standard radiation therapy based on their Radiosensitivity Index score
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of progression-free survival and quality of life
What Are the Treatments Tested in This Trial?
Interventions
- Genomically Guided Radiation Therapy
Genomically Guided Radiation Therapy is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
H. Lee Moffitt Cancer Center and Research Institute
Lead Sponsor